List of Excipients in Branded Drug METOPROLOL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	HYPROMELLOSE
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	PARAFFIN
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	POLYETHYLENE GLYCOL

Generic Drugs Containing METOPROLOL

Company	Ingredient	NDC	Excipient
Baxter Healthcare Corporation	metoprolol tartrate	36000-033	SODIUM CHLORIDE
Baxter Healthcare Corporation	metoprolol tartrate	36000-033	WATER
Cardinal Health 107 LLC	metoprolol tartrate	55154-4451	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in METOPROLOL?

# Of NDCs	Excipient
6	SODIUM CHLORIDE
5	WATER

Metoprolol Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

Metoprolol is a mature, low-cost beta blocker with two commercially important oral forms: immediate-release metoprolol tartrate and extended-release metoprolol succinate. The active ingredient has limited core patent protection, so commercial value is concentrated in excipient-enabled performance, differentiated delivery, adherence, pediatric usability, combination products, and manufacturing efficiency.

The strongest formulation opportunities are controlled release, dose flexibility, taste-masked liquids, multiparticulates, lower-pill-burden products, and supply-chain improvements. Generic competition is established, while biosimilar risk is not relevant because metoprolol is a small-molecule drug.

What metoprolol formulations are commercially available?

Metoprolol is marketed primarily as metoprolol tartrate and metoprolol succinate. The salts have different release profiles and are not interchangeable on a milligram-for-milligram basis.

Product type	Active form	Typical release	Main clinical use	Formulation priority
Immediate-release tablets	Metoprolol tartrate	Immediate	Hypertension, angina, post-myocardial infarction management	Rapid dissolution, content uniformity, low manufacturing cost
Extended-release tablets	Metoprolol succinate	Once daily	Hypertension, angina, heart failure	Controlled release, dose linearity, food-effect control
Oral solutions or suspensions	Usually tartrate or compounded metoprolol	Immediate	Pediatric, geriatric, dysphagia, dose titration	Taste masking, preservative system, dosing accuracy
Extemporaneous compounded products	Salt varies	Usually immediate	Institutional and specialty use	Stability, microbial control, packaging compatibility

The FDA-approved Toprol-XL label identifies metoprolol succinate extended-release tablets as once-daily products and describes a controlled-release dosage form designed to provide a controlled delivery of metoprolol over the dosing interval (U.S. Food and Drug Administration [FDA], 2023a). Lopressor contains metoprolol tartrate in an immediate-release tablet and injectable form (FDA, 2023b).

Metoprolol succinate has a different molecular weight from metoprolol tartrate. Conversion requires attention to equivalent metoprolol base content and the approved product labeling rather than simple salt substitution.

How do excipients differ between metoprolol tartrate and metoprolol succinate?

Immediate-release metoprolol tartrate products generally use conventional tablet excipients. Extended-release metoprolol succinate products require a release-controlling architecture.

Immediate-release metoprolol tartrate excipients

Common excipient classes include:

• Lactose or another soluble diluent
• Microcrystalline cellulose
• Maize starch or pregelatinized starch
• Povidone or another binder
• Crospovidone or croscarmellose sodium as a disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Film-coating polymers, plasticizers, and colorants

The target profile is rapid tablet breakup and dissolution without excessive sensitivity to compression force. Metoprolol tartrate is highly water soluble, so the formulation challenge is usually not solubilization. It is achieving robust disintegration, dose uniformity, acceptable hardness, and low-cost high-speed manufacture.

Extended-release metoprolol succinate excipients

Extended-release systems can use:

• Hypromellose or another hydrophilic matrix polymer
• Microcrystalline cellulose as a structural diluent
• Ethylcellulose or other water-insoluble polymers
• Polyethylene glycol as a coating plasticizer
• Colloidal silicon dioxide
• Sodium stearyl fumarate or magnesium stearate
• Titanium dioxide and approved colorants
• Functional coating systems for multiparticulate or matrix-based release

The commercial reference product uses a controlled-release design rather than a conventional immediate-release tablet. Generic manufacturers may use different excipient systems if they meet the applicable pharmaceutical equivalence, bioequivalence, dissolution, stability, and quality requirements.

The relevant development objective is not simply slower dissolution. It is reproducible exposure across the intended dosing interval, including consistent performance under different gastrointestinal conditions.

What excipient strategy is strongest for extended-release metoprolol?

A hydrophilic matrix is usually the most practical platform for a low-cost generic or line extension. Upon contact with gastrointestinal fluid, the polymer hydrates and forms a gel layer. Drug diffusion and matrix erosion then control release.

Hydrophilic matrix strategy

A matrix system can provide:

• Lower manufacturing complexity than a multiparticulate system
• Straightforward tablet compression
• Flexible dose strengths
• Lower packaging and equipment costs
• Good scalability for high-volume generic production

The main development risks are dose dumping, polymer grade variability, sensitivity to compression, and changes in release caused by food or gastrointestinal motility.

Key optimization variables include polymer viscosity, polymer concentration, particle size, tablet porosity, compression force, lubricant level, and coating weight. A formulation that releases metoprolol correctly at one strength may not scale linearly to another strength.

Multiparticulate strategy

Pellets, mini-tablets, or coated granules can create a more consistent gastrointestinal distribution than a single monolithic tablet. The approach can reduce sensitivity to local gastrointestinal conditions and support sprinkle or dispersible presentations.

Commercial disadvantages include:

• More complex coating equipment
• Higher process-development cost
• Greater risk of coat defects
• More demanding particle-size control
• Higher analytical burden for dose uniformity and release testing

Multiparticulates are most attractive where the product has a meaningful patient-use advantage, such as administration to patients who cannot swallow tablets.

Osmotic and membrane-controlled systems

Osmotic or membrane-controlled systems can deliver a more programmable release profile, but they generally require higher manufacturing investment. They are less attractive for conventional generic competition unless they provide a clinically meaningful benefit or support a differentiated regulatory strategy.

What formulation patents protect metoprolol products?

The core metoprolol molecule and the principal branded dosage-form patents are mature. The commercial patent opportunity is more likely to arise from formulation-specific claims than from the active ingredient.

IP category	Commercial status	Strategic relevance
Metoprolol active ingredient	Mature and off-patent	Minimal standalone exclusivity
Metoprolol tartrate immediate-release tablets	Generic competition established	Cost, supply, and quality advantages matter
Metoprolol succinate extended-release tablets	Generic competition established	Release technology and bioequivalence remain important
Controlled-release delivery systems	Older platform patents largely expired or near the end of life	New claims must focus on defined compositions, processes, or performance
Taste-masked liquids and pediatric products	Potentially protectable	Formulation, flavor, preservative, and dosing-device claims
Multiparticulate or sprinkle products	Potentially protectable	Particle architecture, coating, capsule, and administration method
Combination products	Potentially protectable	Fixed-dose composition and therapeutic-use claims
Manufacturing processes	Potentially protectable as trade secrets or patents	Scale, yield, coating uniformity, and impurity control

The FDA Orange Book is relevant for approved drug patents and exclusivity, but a formulation patent is commercially useful only if its claims cover the marketed product and can withstand validity and infringement challenges. Because metoprolol has extensive generic availability, a new entrant should not rely on broad claims directed only to “metoprolol in an extended-release tablet.”

Narrower claim sets may be more defensible if they specify:

• Polymer identity and viscosity grade
• Defined dissolution windows
• Release performance across pH conditions
• Multiparticulate coating thickness
• Stability after moisture exposure
• Low-dose pediatric composition
• Preservative and pH system for liquid products
• Specific manufacturing parameters that produce a critical product attribute

When does metoprolol lose exclusivity?

Metoprolol has already lost market exclusivity for its principal immediate-release and extended-release products. The relevant commercial issue is not the expiration of basic metoprolol exclusivity. It is whether a new formulation creates a separate, enforceable period of protection.

FDA regulatory status

Metoprolol tartrate and metoprolol succinate are FDA-approved prescription drugs with multiple approved generic products. Generic metoprolol products are generally approved through abbreviated new drug applications under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

No biosimilar pathway applies. Metoprolol is a chemically synthesized small molecule, not a biologic.

A new dosage form may require:

• An ANDA if it is pharmaceutically equivalent to a reference product
• A 505(b)(2) application if it relies partly on published literature or an approved product but introduces a change such as a new dosage form, route, strength, or formulation
• A new drug application if the product contains a new active ingredient or presents a sufficiently distinct development program

What is the Paragraph IV challenge risk for metoprolol?

Paragraph IV risk is highest for newly launched differentiated formulations, not for the mature basic products.

A generic applicant may file a Paragraph IV certification against an unexpired Orange Book patent listed for a reference product. For legacy metoprolol products, the practical barrier is low because multiple generic products already compete in the market. For a new metoprolol formulation, a patent owner could list formulation or method-of-use patents if the FDA listing requirements are satisfied.

The most relevant litigation triggers would be:

1. A new extended-release formulation with a patent covering dissolution performance.
2. A pediatric liquid with a patent covering composition and stability.
3. A sprinkle or capsule product with a patent covering multiparticulate architecture.
4. A fixed-dose combination with a patent covering the combination or use.
5. A manufacturing patent alleged to be practiced by a generic competitor.

A patent owner should expect validity challenges based on obviousness, written description, enablement, and lack of technical effect. A generic challenger may also argue that the asserted claims do not cover its excipient system or manufacturing process.

What excipient-driven commercial opportunities exist for metoprolol?

1. Pediatric oral liquid

A metoprolol liquid can address patients who cannot swallow tablets and patients requiring small dose adjustments. The primary technical problems are bitterness, dose uniformity, microbial control, and chemical stability.

A commercial formulation could use:

• A buffered aqueous vehicle
• A validated preservative system
• A suspending polymer if the drug is not fully solubilized
• Flavor and sweetener systems
• A calibrated oral syringe
• Light- and moisture-protective packaging

A ready-to-use liquid is more commercially attractive than a product that requires pharmacy compounding. The formulation must avoid excipients with pediatric tolerability concerns at the intended dose.

2. Taste-masked immediate-release product

Metoprolol’s bitter taste can limit liquid and chewable presentations. Taste masking may use polymer coatings, ion-exchange resins, lipid matrices, cyclodextrin systems, or multiparticulate encapsulation.

The strongest product concept is a dose-flexible formulation that maintains rapid release after swallowing while suppressing oral cavity release. A taste-masked product can support pediatric, geriatric, and dysphagia markets.

3. Sprinkle or dispersible extended-release dosage form

An extended-release capsule containing coated pellets could allow administration by sprinkling contents onto soft food. The product must preserve pellet integrity and release performance after opening, handling, and administration.

Critical label restrictions may include prohibitions on crushing, chewing, or grinding. Those restrictions should be reflected in the excipient and coating strategy from the start.

4. Lower pill burden

Metoprolol is frequently used with antihypertensive, lipid-lowering, antiplatelet, and heart-failure therapies. A fixed-dose combination could improve adherence, but dose titration is a major constraint because beta-blocker dosing is individualized.

The best candidates are combinations with stable co-prescribing patterns and compatible dose ratios. Formulation development must manage different release requirements, chemical compatibility, and dose adjustment needs.

5. Abuse-deterrent and tamper-resistant designs

The clinical need is limited compared with opioids, so an abuse-deterrent metoprolol product is unlikely to justify substantial cost unless it addresses a specific institutional or public-health requirement. Conventional controlled-release technology should not be marketed as abuse deterrence without supporting abuse-deterrence studies.

6. Manufacturing-cost reduction

For a mature generic, the most defensible commercial advantage may be operational rather than clinical. Opportunities include:

• Direct compression with fewer processing steps
• Lower-cost polymer grades
• Continuous manufacturing
• Reduced coating time
• Improved tablet robustness
• Reduced sticking and picking
• Lower impurity formation
• Improved moisture-barrier packaging
• Dual sourcing of critical excipients

A process patent or trade-secret program can protect coating conditions, granulation parameters, in-process controls, and scale-up methods even when the composition itself is not novel.

How strong is the metoprolol patent estate?

The estate is weak for the active ingredient and conventional immediate-release tablets. It is moderate for a technically differentiated extended-release, pediatric, multiparticulate, or combination product.

Patent strategy	Relative strength	Reason
Broad claim to metoprolol tablet	Low	Mature prior art and extensive generic use
Conventional excipient substitution	Low	Usually predictable to a skilled formulator
Defined extended-release profile with unexpected benefit	Moderate	Stronger if supported by comparative data
Pediatric liquid with stability and taste benefit	Moderate	Claims may be narrow but commercially focused
Multiparticulate sprinkle product	Moderate	More structural limitations and manufacturing detail
New fixed-dose combination	Moderate to high	Depends on clinical and formulation distinctiveness
Manufacturing process with measurable quality improvement	Moderate	Can be valuable as a process patent or trade secret
New therapeutic indication	Variable	Requires clinical support and method-of-use claim scope

A formulation patent is strongest when the excipient choice produces an unexpected result, such as reduced food effect, improved dose proportionality, lower variability, extended stability, or a meaningful patient-use advantage. Routine selection of hypromellose, lactose, magnesium stearate, or standard coating agents usually provides limited patent strength by itself.

Which companies are challenging or competing with metoprolol products?

Metoprolol competition is fragmented across generic manufacturers and branded or authorized-generic channels. Major U.S. generic suppliers have included companies such as:

• Amneal Pharmaceuticals
• Dr. Reddy’s Laboratories
• Mylan, now part of Viatris
• Sandoz
• Teva Pharmaceuticals
• Zydus Pharmaceuticals
• Lupin
• Rising Pharmaceuticals
• Ingenus Pharmaceuticals
• Apotex in relevant markets

The exact supplier set varies by strength, dosage form, national market, and procurement contract. Competition is driven by FDA approval status, manufacturing reliability, wholesaler access, shortage performance, pricing, and therapeutic interchangeability.

For a new entrant, the commercial hurdle is not merely obtaining approval. It is securing predictable supply, payer or wholesaler acceptance, and sufficient gross margin after price erosion.

What generic launch scenarios exist for a new metoprolol product?

Conventional immediate-release generic

This has the lowest technical risk and the highest price competition. The opportunity is strongest where the product improves supply reliability, offers an under-supplied strength, or reduces manufacturing cost.

Extended-release generic

This requires more extensive dissolution and bioequivalence work. It can support better margins than immediate-release tablets, but the market already includes multiple generic products.

Pediatric liquid

This has a smaller addressable market but greater differentiation. A ready-to-use, palatable product with an integrated dosing device could obtain stronger pricing than a conventional tablet.

Sprinkle capsule

This offers a patient-use advantage and may support a 505(b)(2) or differentiated generic strategy, depending on the reference product and regulatory pathway.

Fixed-dose combination

This has the highest potential commercial differentiation but requires clinical, regulatory, and lifecycle planning. Dose flexibility and titration may limit adoption in heart failure and other indications.

What manufacturing and IP barriers affect metoprolol commercialization?

The main manufacturing barriers are release reproducibility, scale-up, excipient variability, and analytical discrimination.

Important control points include:

• Polymer viscosity and substitution level
• Particle-size distribution
• Blend uniformity
• Tablet porosity
• Compression force
• Coating weight gain
• Residual solvent control
• Moisture uptake
• Dissolution across multiple pH media
• Stability under accelerated and long-term conditions
• Dose uniformity across strengths

For extended-release products, dissolution testing must distinguish meaningful formulation differences. A simple single-point specification can be inadequate for development and litigation purposes. Multi-point profiles across pH conditions are more useful for demonstrating release robustness.

Geographic coverage should be planned separately for the United States, European Union, Japan, Canada, and emerging markets. Regulatory definitions of generic equivalence, reference products, excipient acceptability, and substitution vary by jurisdiction. A formulation that is straightforward under the U.S. ANDA pathway may require a different bridging strategy elsewhere.

How does metoprolol compare with competing beta blockers?

Drug	Common oral formulation opportunity	Excipient and delivery differentiation
Metoprolol	Tartrate IR and succinate ER	Strongest opportunity in release control, liquids, and sprinkle products
Atenolol	Immediate-release tablet	Low-cost formulations, lower technical complexity
Bisoprolol	Immediate-release tablet	Dose flexibility and combination products
Carvedilol	Immediate-release and extended-release forms	Solubility, food effect, and controlled release
Propranolol	Immediate-release and extended-release forms	Pediatric liquids, taste masking, and release control
Nebivolol	Immediate-release tablet	Lower-volume specialty and combination opportunities

Metoprolol’s commercial advantage is the large installed base and established clinical use. Its disadvantage is intense generic price competition. The most attractive strategy is a formulation that solves a specific administration or adherence problem rather than another conventional tablet.

What revenue exposure exists for metoprolol formulation strategies?

Revenue exposure is concentrated in high-volume generic tablets, but unit prices are low. A conventional product can generate meaningful revenue only through scale, low cost, and reliable supply.

Higher-margin opportunities include:

• Pediatric and geriatric dosage forms
• Institutional formulations
• Specialty pharmacy products
• Adherence-oriented delivery systems
• Combination products
• Authorized-generic arrangements
• Contract manufacturing and private-label supply
• Products launched in markets with limited approved competitors

Revenue risk includes rapid price erosion, pharmacy substitution, wholesaler consolidation, tender-driven pricing, and inventory overhang. A differentiated excipient platform can reduce direct price comparison, but only if the product obtains regulatory recognition and meaningful channel access.

Key Takeaways

• Metoprolol is a mature small-molecule drug with no biosimilar risk and limited core patent value.
• Metoprolol tartrate is primarily an immediate-release, low-cost generic opportunity.
• Metoprolol succinate is the stronger platform for controlled-release and excipient-driven differentiation.
• The most attractive product concepts are pediatric liquids, taste-masked dosage forms, sprinkle capsules, multiparticulates, and selected fixed-dose combinations.
• Standard excipients alone rarely create strong patent protection.
• Patent strength improves when excipient composition is linked to an unexpected release, stability, bioequivalence, or patient-use result.
• Generic launch risk is highest from price erosion and channel competition, not from basic active-ingredient patents.
• Manufacturing know-how, polymer control, coating uniformity, and dissolution robustness may be more valuable than broad composition claims.
• A new metoprolol product should be designed around a specific commercial problem: swallowing difficulty, dose titration, adherence, supply reliability, or lower manufacturing cost.

FAQs About Metoprolol Excipient and Formulation Opportunities

Can metoprolol be formulated as a pediatric oral liquid?

Yes. A pediatric oral liquid can use a solution or suspension approach, with taste masking, pH control, preservative protection, and an oral syringe. The commercial opportunity is strongest for a ready-to-use product that reduces reliance on pharmacy compounding.

Which excipient is best for metoprolol extended release?

Hydrophilic polymers such as hypromellose are common starting points, but no single excipient is universally optimal. Polymer grade, concentration, tablet porosity, compression, and coating conditions determine the final release profile.

Can metoprolol extended-release tablets be crushed?

Generally, extended-release metoprolol products should not be crushed or chewed because mechanical disruption can alter the release profile. Product-specific labeling controls whether a tablet may be split or whether a capsule may be opened and sprinkled.

Is metoprolol succinate patent protected?

The original branded extended-release product patents are mature, and generic metoprolol succinate products are approved. New formulation patents may still be possible if they cover a genuinely differentiated composition, process, or performance profile.

Is metoprolol suitable for a fixed-dose combination product?

It can be, but individualized beta-blocker titration limits some combinations. The strongest candidates are combinations with stable dosing patterns, compatible release requirements, and a clear adherence or pill-burden advantage.

References

1. U.S. Food and Drug Administration. (2023a). Toprol-XL (metoprolol succinate) extended-release tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2023b). Lopressor (metoprolol tartrate) tablets and injection: Prescribing information.
3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024b). Orange Book: Approved drug products with therapeutic equivalence evaluations.
5. U.S. Food and Drug Administration. (2019). ANDAs for certain highly soluble, highly permeable drugs: Product-specific guidance.
6. U.S. Food and Drug Administration. (2017). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
7. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: U.S. Pharmacopeial Convention.